Home
Drugs
Corticosteroid

Corticosteroid

Drug

Also known as: deflazacort

Related News

Priovant's Brepocitinib Shows Positive Phase 3 Results in Dermatomyositis Trial

Mar 29, 2026

Priovant Therapeutics' brepocitinib demonstrated significant efficacy in the Phase 3 VALOR trial for dermatomyositis, meeting its primary endpoint with a 15.3-point greater improvement in Total Improvement Score versus placebo at Week 52. The treatment showed meaningful corticosteroid tapering and improvements across all nine key secondary endpoints, with benefits sustained through one year. Additional analyses revealed rapid itch reduction and improved skin-related quality of life in patients.

Gene Therapy for Knee Osteoarthritis Advances; India Plans Regulatory Framework

Mar 09, 2026

Five intra-articular gene therapy platforms for knee osteoarthritis are in human trials in the US, while India prepares regulatory guidelines for mRNA, gene and cell therapies to accelerate innovation.

FDA Clears NexEos Bio IND for NTX-1024 Phase II/III Trial in Vernal Keratoconjunctivitis

Feb 26, 2026

The FDA cleared NexEos Bio's IND application to proceed with a Phase II/III trial of NTX-1024 ophthalmic solution for vernal keratoconjunctivitis, following positive results from a 15-patient study in Mexico.

TREMFYA® Shows Sustained Remission in Ulcerative Colitis Through Week 140

Feb 21, 2026

Long-term data from the QUASAR extension study show TREMFYA® maintained clinical remission in over 80% of ulcerative colitis patients at Week 140, with more than half achieving endoscopic remission and no new safety concerns observed.

Ocular Therapeutix Reports Positive Phase 3 SOL-1 Trial Results for AXPAXLI in Wet AMD

Feb 14, 2026

Ocular Therapeutix announced positive topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting primary and durability endpoints with high statistical significance.

PTC Therapeutics Withdraws Ataluren NDA for Duchenne Muscular Dystrophy

Feb 13, 2026

PTC Therapeutics has withdrawn its New Drug Application resubmission for ataluren (Translarna) for nonsense mutation Duchenne muscular dystrophy after the FDA indicated the submission lacked substantial evidence of effectiveness.

PTC Therapeutics Withdraws FDA Application for Duchenne Drug Translarna After Decade-Long Effort

Feb 13, 2026

PTC Therapeutics has withdrawn its New Drug Application for Translarna (ataluren) for Duchenne muscular dystrophy after the FDA indicated the data were unlikely to meet approval thresholds, ending a pursuit spanning more than a decade.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07546097	Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）	RECRUITING	PHASE4
NCT07513142	PPP Versus Corticosteroid for Thigh Muscle Injuries	ENROLLING_BY_INVITATION	PHASE4
NCT07474714	Hyaluronic Acid Injection in Idiopathic Carpal Tunnel Syndrome; is it Effective as Local Corticosteroids	NOT_YET_RECRUITING	PHASE3
NCT07223580	A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi	RECRUITING	PHASE4
NCT07199192	Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial	NOT_YET_RECRUITING	PHASE4
NCT07098897	To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy	ACTIVE_NOT_RECRUITING	PHASE3
NCT07039019	Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis	RECRUITING	EARLY_PHASE1
NCT06952686	A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants	WITHDRAWN	PHASE3
NCT06905860	Intra-articular Infiltration of Platelet-Rich Fibrin vs Corticosteroid in Mild to Moderate Knee Osteoarthritis	NOT_YET_RECRUITING	PHASE4
NCT06780085	A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)	RECRUITING	PHASE2